Exact Sciences Corp (EXAS)

Price$0.00

Value ScoreF

Growth ScoreB

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)98.22%

Price vs S&P 500 (4W)6.43%

VGM Score53.49

Market Capitalization$20.03B

All Metrics

P/CF (Annual)40.75x

Book Value / Share (Quarterly)$12.58

P/TBV (Annual)13.02x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)15.92%

Cash Flow / Share (Quarterly)$1.48

Price vs S&P 500 (YTD)8.19%

Gross Margin (TTM)69.69%

Net Profit Margin (TTM)-6.40%

EPS (TTM)$-1.10

10-Day Avg Trading Volume4.06M

EPS Excl Extra (TTM)$-1.10

Revenue Growth (5Y)16.84%

EPS (Annual)$-1.10

ROI (Annual)-4.39%

Gross Margin (Annual)69.69%

Net Profit Margin (5Y Avg)-23.09%

Cash / Share (Quarterly)$5.06

Revenue Growth QoQ (YoY)23.12%

ROA (Last FY)-3.55%

Revenue Growth TTM (YoY)17.69%

EBITD / Share (TTM)$-0.43

ROE (5Y Avg)-19.21%

Operating Margin (TTM)-6.35%

Cash Flow / Share (Annual)$1.48

P/B Ratio8.34x

P/B Ratio (Quarterly)8.03x

Net Income / Employee (Annual)$-29,300

EV / Revenue (TTM)6.59x

Net Interest Coverage (TTM)-15.18x

ROA (TTM)-3.57%

EPS Incl Extra (Annual)$-1.10

Current Ratio (Annual)2.43x

Quick Ratio (Quarterly)1.97x

3-Month Avg Trading Volume4.50M

52-Week Price Return136.92%

EV / Free Cash Flow (Annual)75.98x

Revenue / Employee (TTM)$457,300

Tangible BV / Share (Quarterly)$7.76

P/S Ratio (Annual)6.17x

Asset Turnover (Annual)0.55x

52-Week High$104.98

Operating Margin (5Y Avg)-25.81%

EPS Excl Extra (Annual)$-1.10

CapEx CAGR (5Y)-15.13%

Tangible BV CAGR (5Y)1.30%

26-Week Price Return96.35%

Quick Ratio (Annual)1.97x

13-Week Price Return3.10%

Total Debt / Equity (Annual)0.97x

Current Ratio (Quarterly)2.43x

Enterprise Value$21.41B

Revenue / Share Growth (5Y)11.76%

Asset Turnover (TTM)0.56x

Book Value / Share Growth (5Y)-2.15%

Revenue / Employee (Annual)$457,300

Inventory Turnover (Annual)5.99x

Pretax Margin (Annual)-6.28%

Cash / Share (Annual)$5.06

3-Month Return Std Dev3.30%

Gross Margin (5Y Avg)71.24%

Net Income / Employee (TTM)$-29,300

ROE (Last FY)-8.66%

Net Interest Coverage (Annual)-23.91x

EPS Basic Excl Extra (Annual)$-1.10

P/FCF (TTM)70.98x

Receivables Turnover (TTM)11.86x

EV / Free Cash Flow (TTM)75.98x

Total Debt / Equity (Quarterly)0.97x

EPS Incl Extra (TTM)$-1.10

Receivables Turnover (Annual)11.86x

ROI (TTM)-4.35%

P/S Ratio (TTM)6.17x

Pretax Margin (5Y Avg)-25.99%

Revenue / Share (Annual)$17.21

Tangible BV / Share (Annual)$7.76

Forward P/E582.83x

Price vs S&P 500 (52W)122.23%

Year-to-Date Return3.30%

5-Day Price Return1.02%

EPS Normalized (Annual)$-1.10

ROA (5Y Avg)-8.60%

Net Profit Margin (Annual)-6.40%

Month-to-Date Return1.48%

Cash Flow / Share (TTM)$-0.44

EBITD / Share (Annual)$-0.43

Operating Margin (Annual)-6.35%

LT Debt / Equity (Annual)0.97x

P/CF (TTM)40.75x

ROI (5Y Avg)-10.23%

LT Debt / Equity (Quarterly)0.97x

EPS Basic Excl Extra (TTM)$-1.10

P/TBV (Quarterly)13.02x

P/B Ratio (Annual)8.03x

Inventory Turnover (TTM)5.99x

Pretax Margin (TTM)-6.28%

Book Value / Share (Annual)$12.58

Price vs S&P 500 (13W)7.56%

Beta-0.16x

P/FCF (Annual)71.07x

Revenue / Share (TTM)$17.11

ROE (TTM)-8.51%

52-Week Low$38.81

vGradeF

gGradeB

mGradeB

vgmGradeC

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.34

Industry Peers — Health Services(28)

Symbol	Value Score	Growth Score	Momentum Score	Price
EXASExact Sciences Corp	F	B	B	$0.00
NTRANatera, Inc. Common Stock	F	A	C	$215.31
DGXQuest Diagnostics Inc.	C	D	C	$200.29
LHLabcorp Holdings Inc.	C	D	C	$265.15
GHGuardant Health, Inc. Common Stock	F	A	B	$125.61
CAICaris Life Sciences, Inc. Common Stock	F	A	D	$16.49
CELCCelcuity Inc. Common Stock	—	—	C	$88.28
RDNTRadNet, Inc. Common Stock	D	C	C	$54.34
VCYTVeracyte, Inc.	D	A	B	$48.73
GRALGRAIL, Inc. Common Stock	D	A	C	$59.98
FTREFortrea Holdings Inc. Common Stock	B	F	A	$16.08

About

Exact Sciences develops cancer screening and diagnostic tests for the United States and international markets. Its primary offerings include Cologuard, a noninvasive stool-based DNA test for colorectal cancer screening, and Oncotype DX, a precision oncology suite providing tissue-based genomic testing for cancer risk assessment and treatment guidance. The company is expanding its portfolio with OncoExTra, a liquid-based genomic profiling test, and a pipeline of blood-based solutions for cancer detection and molecular residual disease monitoring.